Reason: MRNA's within-cycle move has extended further - 30D +153.24%, 1-year change +463.51%->+463.91% - still the sharpest number on the desk; news pulled 2026-08-28 shows a same-day settled COVID-19 vaccine IP litigation headline, a plausible partial driver, but it does not account for the scale of the year-long re-rate. AMGN and TMO both sit near fresh 52-week highs in breakout/uptrend regimes with strongly positive 1-year change and 1-year alpha; VRTX rounds out a cohort where all four names are golden-crossed and above their 200-day with positive 1-year alpha.

Tape Read

$MRNA remains the most extreme move on the desk: price $137.99, RSI 63.5 (down from a near-overbought 71.6 last cycle), golden-cross, regime pullback, thesis unrated, 7D -4.89%, 30D +153.24% (up from +149.92%), 1-year change +463.91% (up from +453.51%), 166.6% above its 200-day average (vs 200-day), 1-year alpha +444.04 — still -21.89% off its 52-week high despite the size of the move. News pulled 2026-08-28 (receipt fresh, ok: true): the top item is "Moderna shares rise after settling COVID-19 vaccine technology legal battle," dated 2026-08-28 — a plausible partial driver for the recent bounce, but a single litigation settlement does not explain a 1-year change in the hundreds of percent; research/stock-events/ shows Q1 2026 results (2026-07-31) and a scheduled Q3 print (2026-11-05), neither of which lands on this window. The broader magnitude of the year-long re-rate remains unaccounted for beyond these receipts. $AMGN: price $432.42, RSI 63.8, golden-cross, regime breakout, thesis unrated, 7D -1.59%, 30D +11.55%, -3.27% off its 52-week high, 1-year change +51.4%, vs 200-day +21.5%, 1-year alpha +31.53 — genuinely intact strength, not just a short-window pop. $TMO: price $622.18, RSI 66.2, golden-cross, regime uptrend, thesis intact, 7D -1.14%, 30D +7.93%, -3.84% off its high, 1-year change +27.04%, vs 200-day +16.2%, 1-year alpha +7.17. $VRTX: price $541.69, RSI 61.4, golden-cross, regime breakout, thesis unrated, 7D -1.15%, 30D +12.07%, -2.52% off its high, 1-year change +38.17%, vs 200-day +16.9%, 1-year alpha +18.3. Source: full-scan pre-computed summaries as of the 2026-08-28 close — biotech ($MRNA, $VRTX, $TMO) and biotech-scan ($AMGN, tracked outside the core biotech watchlist); news receipt latest.

• $MRNA — WATCH: 7D -4.89%, 30D +153.24%, 1-year change +463.91% — the desk's sharpest print this cycle, now larger than last week's; a same-day litigation-settlement headline is a plausible partial driver but does not explain the full magnitude.
• $AMGN — PROMOTE: RSI 63.8, golden-cross, regime breakout, -3.27% off its 52-week high, 1-year change +51.4%, 1-year alpha +31.53 — genuinely intact, not just extended.
• $TMO — WATCH: golden-cross, regime uptrend, thesis intact, 1-year change +27.04%, 1-year alpha +7.17.
• $VRTX — WATCH: golden-cross, regime breakout, 1-year change +38.17%, 1-year alpha +18.3.

Lead pick: $MRNA's move is the largest number on the desk this cycle by a wide margin and has grown further since last week — a same-day litigation-settlement headline gives a partial, unconfirmed-magnitude driver, but the size and speed still argue for treating it as an outlier requiring verification rather than a clean promote. $AMGN is the cleanest confirmed leader: near a fresh high, RSI elevated but the year (+51.4%) and alpha (+31.53) back up the breakout regime rather than just a short-window extension.

Sources

• Tape data (price/RSI/SMA/returns/1-year change/1-year alpha): full-scan pre-computed summaries as of the 2026-08-28 close — biotech ($MRNA, $VRTX, $TMO) and biotech-scan ($AMGN, tracked outside the core biotech watchlist).
• News check (MRNA move): latest (fetched 2026-08-28, ok: true, not stale) and research/stock-events/ (no event dated to this window).